The Valens Company submits site evidence package to Health Canada for manufacturing facility in the GTA
The GTA Facility is expected to receive its licence in the second quarter of 2021, after which Valens expects to begin manufacturing products at the facility.
Alcohol & Cannabis
Food & Beverage
KELOWNA — The Valens Company Inc., a manufacturer of cannabis products, announced on Feb. 23 that it had submitted a site evidence package to Health Canada under its existing micro-processing licence application for the Company’s third facility in Canada, located in the Greater Toronto Area (“GTA Facility”).
The GTA Facility is now in the final stages of construction and will provide an additional 30,000 square feet of capacity, focused on the formulation, co-packing, and manufacturing of cannabis-infused beverages and other customized 2.0 and 3.0 products using SōRSE by Valens emulsion technology.
“Thanks to our exceptional team, we are now one step closer to bringing the GTA Facility online despite initial delays caused by the pandemic,” said Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company. “As of Q4 2020 and according to Headset data, Valens holds approximately 5.2 percent of cannabis-infused beverage market share in Alberta, British Columbia, and Ontario, with just one partner in this product category. With this additional manufacturing capacity, we look forward to expanding our beverage product offering and market share through additional mandates in this category with new and existing partners.”
The custom-designed facility features an integrated system that can fill 100 bottles per minute with the added ability to increase future output to prepare for expected national demand. The GTA Facility supports production of PET bottles, canned formats, and smaller formats for a shot-type product, in addition to offering both carbonated and non-carbonated beverages. Valens’ beverage program has been designed to support custom manufacturing and white label partners and is staffed with experts in formulation and product design, leveraging the Company’s existing testing and analytics capabilities.
The GTA Facility is expected to receive its licence in the second quarter of 2021, after which Valens expects to begin manufacturing products at the facility and begin commercializing and shipping out products in the second half of fiscal 2021.